"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
Trial Parameters
Brief Summary
evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma
Eligibility Criteria
Inclusion Criteria: 1. Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70); 2. Pre-survival time \> 6 months; 3. The pathological tissue was confirmed as NK/T cell lymphoma (the pathological report of the first three months of enrollment could be accepted) (Note: If there is any doubt about the pathological diagnosis, domestic third-party consultation could be organized); 4. Clinical stage Ⅰ to Ⅱ (CA stage) with at least one measurable lesion; 5. Acceptable hematological indicators, no contraindications to chemotherapy; Neutrophil absolute value ≥1.0×10\^9 /L, platelet ≥75×10\^9 /L, hemoglobin ≥80g/L (except patients with lymphoma bone marrow infiltration); 6. Liver function: direct bilirubin ≤1.5× upper limit reference value; Glutamic pyruvic transaminase or glutamic oxalacetic transaminase ≤2.5× upper limit reference value; Alkaline phosphatase ≤3×ULN in non-bone invaded patients; 7. Renal function: serum creatinine ≤1.5×ULN; 8. Female and male patients of reprod